Диссертация (1091663), страница 16
Текст из файла (страница 16)
– 2016. – Vol. 216. – P. 148 – 156.94)Cheng G. Alpha interferon is a powerful adjuvant for a recombinant proteinvaccine against foot-and-mouth disease virus in swine, and an effective stimulus of invivo immune response. / Cheng G., Zhao X., Yan W., Wang W., Zuo X., Huang K.,Liu Y., Chen J., Wang J., Cong W., Liu M., Gao H., Chen J., Lu Y., Zheng Z. //Vaccine.
– 2007. – Vol. 25. – No 28. – P. 5199 – 520895)Asif M. Cytokines as adjuvants for avian vaccines. / Asif M., Jenkins K.A.,Hilton L.S., Kimpton W.G., Bean A.G., Lowenthal J.W. // Immunology and CellBiology. – 2004. – Vol. 82. – No 6. – P. 638–643.96)Babiuk L.A. Application of interferons in the control of infectious diseasesof cattle. / Babiuk L.A., Sordillo L.M., Campos M., Hughes H.P., Rossi-Campos A.,Harland R. // Journal of Dairy Science. – 1991. – Vol. 74.
No 12. – P. 4385 – 4398.10297)Tafalla C. Adjuvants and immunostimulants in fish vaccines: currentknowledge and future perspectives. / Tafalla C., Bøgwald J., Dalmo R.A. // Fish andShellfish Immunology. – 2013. – Vol. 35. No 6. – P. 1740 – 1750.98)Hung L. Adjuvant effects of chicken interleukin-18 in avian Newcastledisease vaccine. / Hung L., Li H., Lien Y., Wu M.L., Chaung H.C.
// Vaccine. –2010. – Vol. 28. – No 5. – P. 1148 – 1155.99)Huo S. Chicken IL-7 as a potent adjuvant enhances IBDV VP2 DNAvaccine immunogenicity and protective efficacy. / Huo S., Zuo Y., Li N., Li X.,Zhang Y., Wang L., Liu H., Zhang J., Cui D., He P., Xu J., Li Y., Zhu X., Zhong F. //Veterinary Microbiology. – 2016. – Vol. 193. – P. 145 – 155.100)Kotla S. DNA vaccine (P1-2A-3C-pCDNA) co-administered with BovineIL-18 gives protective immune response against Foot and Mouth Disease in cattle.
/Kotla S., Sanghratna Vishanath B., Reddy G.R. // Veterinary Microbiology. – 2016. –Vol. 193. – P. 106 – 115.101)Chang C. Adjuvant activity of fish type I interferon shown in a virus DNAvaccination model. / Chang C., Sun B., Robertsen B. // Vaccine. – 2015. – Vol. 33. –No 21.
– P. 2442 – 2448.102)Freund J. Sensitization and antibody formation after injection of tubercleBacilli and paraffin oil. / Freund J., Casals J., Hosmer E.P. // Proceedings of theSociety for Experimental Biology and Medicine. – 1937. – Vol. 37. – P. 509 – 513.103)Takeda K.
Toll-like receptors. / Takeda K., Kaisho T., Akira S. // AnnualReviwe of Immunology. – 2003. – Vol. 21/ - P. 335 – 376.104)Lavelle E.C. Modified bacterial toxins. / Lavelle E.C., Leavy O., MillsK.H.G. // In: Hackett C.J., and Harn D.A., eds. Vaccine Adjuvants: Immunologicaland Clinical Principles. Totowa, NJ: Humana Press. – 2006.
– P. 111 – 153.105)Steinhagen F. TLR-based immune adjuvants. / Steinhagen F., Kinjo T., BodeC., Klinman D.M. // Vaccine. – 2011. – Vol. 29. No 17. – P. 3341 – 3355.106)Tong N.K. Immunogenicity and safety of an adjuvanted hepatitis B vaccinein pre-hemodialysis and hemodialysis patients. / Tong N.K., Beran J., Kee S.A.,Miguel J.L., Sánchez C., Bayas J.M., Vilella A., de Juanes J.R., Arrazola P., Calbo103Torrecillas F., de Novales EL., Hamtiaux V., Lievens M., Stoffel M. // KidneyInternational. – 2005.
– Vol. 68. – No 5. – P. 2298 – 2303.107)Takeda K. Mechanism for recognition of CpG DNA. / Takeda K., HemmiH., Akira S. // In: Hackett CJ, and Harn DA, eds. Vaccine Adjuvants: Immunologicaland Clinical Principles. Totowa, NJ: Humana Press,. – 2006. – P. 69 – 86.108)Rau H. Efficacy and functionality of lipoprotein OprI from Pseudomonasaeruginosa as adjuvant for a subunit vaccine against classical swine fever. / Rau H.,Revets H., Cornelis P., Titzmann A., Ruggli N., McCullough K.C., Summerfield A. //Vaccine. – 2006. – Vol.
24. – No 22. – P. 4757 – 4768.109)Hajam I.A. Coadministration of flagellin augments immune responses toinactivated foot-and-mouth disease virus (FMDV) antigen. / Hajam I.A., Dar P.A.,Chandrasekar S., Nanda R.K., Kishore S., Bhanuprakash V., Ganesh K. // Researchin Veterinary Science. – 2013. – Vol. 95. – No 3. – P. 936 – 941.110)Qi Y. Incorporation of membraneanchored flagellin or Escherichia coli heat-labile enterotoxin B subunit enhances the immunogenicity of rabies virus-likeparticles in mice and dogs.
/ Qi Y., Kang H., Zheng X., Wang H., Gao Y., Yang S.,Xia X. // Frontiers in Microbiology. – 2015. – Vol. 6. – art. 169.111)Sun Z. Construction and immunogenicity evaluation of an epitope-basedantigen against swine influenza A virus using Escherichia coli heat-labile toxin Bsubunit as a carrier–adjuvant. / Sun Z., Lawson S., Langenhorst R., McCormick K.L.,Brunick C., Opriessnig T., Baker R., Yoon K.J., Zhang W., Huber V.C., Fang Y. //Veterinary Microbiology. – 2013. – Vol. 164.
– No 304. – P. 229 – 238.112)Mayr U.B. Bacterial ghosts as antigen delivery vehicles. / Mayr U.B.,Walcher P., Azimpour C., Riedmann E., Haller C., Lubitz W. // Advanced DrugDelivery Review. – 2005. – Vol. 57. – No 9. – P. 1381 – 1391.113)Jalava K. Bacterial ghosts as vaccine candidates for veterinary applications. /Jalava K., Hensel A., Szostak M., Resch S., Lubitz W. // Journal of ControlledRelease. – 2002. – Vol. 85. – No 1-3. – P. 17 – 25.114)Xia S. Enhanced protective immunity of the chimeric vector-based vaccinerAdV-SFV-E2 against classical swine fever in pigs by a Salmonella bacterial ghost104adjuvant.
/ Xia S., Lei J., Du M., Wang Y., Cong X., Xiang G.T., Li L.F., Yu S., DuE., Liu S., Sun Y., Qiu H.J.. // Veterinary Research. - 2016. – Vol. 47. – No 1. – P.64 – 78.115)Kanzler H. Therapeutic targeting of innate immunity with Toll-like receptoragonists and antagonists. / Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. //Nature Medicine. – 2007. – Vol. 13. – No 5. – P.
552 – 559.116)Stills H.F. Adjuvants and antibody production: dispelling the Mythsassociated with Freund‘s complete and other adjuvants. / Stills H.F. // ILAR Journal.– 2005. – Vol. 46. – No 3. – P. 280 – 293.117)Raffel S. The components of the tubercle Bacillus responsible for thedelayed type of ‗‗infectious‘‘ allergy. / Raffel S. // Journal of Infectious Diseases. –1948. – Vol.
82. – P. 267 – 293.118)Lankester F. The efficacy of alcelaphine herpesvirus-1 (AlHV-1)immunization with the adjuvants Emulsigen and the monomeric TLR5 ligand FliC inzebu cattle against AlHV-1 malignant catarrhal fever induced by experimental viruschallenge. / Lankester F., Lugelo A., Werling D., Mnyambwa N., Keyyu J., KazwalaR., Grant D., Smith S., Parameswaran N., Cleaveland S., Russell G., Haig D. //Veterinary Microbiology. – 2016. – Vol. 195. – P. 144 – 153.119)Штильмaн М.И. Пoлимeры мeдикo-биoлoгичeскoгo нaзнaчeния.
/Штильмaн М.И. // Высoкoмoлeкулярныe сoeдинeния. Сeрия A.- 2010. – Т. 52. № 9. - С. 1551-1569.120)Ferreira S.A. Polymeric nanogels as vaccine delivery systems. / FerreiraS.A., Gama F.M., Vilanova M. // Nanomedicine. – 2013. – Vol. 9. – No 2. – P. 159 –173.121)Rice-Ficht A.C. Polymeric particles in vaccine delivery. / Rice-Ficht A.C.,Arenas-Gamboa A.M., Kahl-McDonagh M.M., Ficht T.A. // Current Opinion inMicrobiology. – 2010. – Vol. 13. – No 1. – P. 106 – 112.122)Muzzarelli R. Chitins and chitosans as immunoadjuvants and non-allergenicdrug carriers.
/ Muzzarelli R. // Marine Drugs. – 2010. – Vol. 8. – No 2. – P. 292 –312.105123)Shibata Y. Chitin particle-induced cell-mediated immunity is inhibited bysoluble mannan: mannose receptor-mediated phagocytosis initiates IL-12 production./ Shibata Y., James Metzger Q.N., Myrvik Q.N. // Journal of Immunology. – 1997. –Vol. 159.
– No 1. – P. 2462 – 2467.124)Bueter C.L. Chitosan but not chitin activates the inflammasome by amechanism dependent upon phagocytosis. / Bueter C.L., Lee C.K., Rathinam V.A.K.,Healy G.J., Taron C.H., Specht C.A., Levitz S.M. // Journal of Biological Chemistry.– 2011. – Vol. 286. – No 41. – P. 35447 – 35455.125)Rauw F. The positive adjuvant effect of chitosan on antigen-specific cell-mediated immunity after chickens vaccination with live Newcastle disease vaccine. /Rauw F., Gardin Y., Palya V, Anbari S., Gonze M., Lemaire S., van den Berg T.,Lambrecht B.
// Veterinary Immunology and Immunopathology. – 2010. – Vol. 134.– No 3-4. – P. 249 – 258.126)Pan L. Induction of mucosal immune responses and protection of cattleagainst direct-contact challenge by intranasal delivery with foot-and-mouth diseasevirus antigen mediated by nanoparticles. / Pan L., Zhang Z., Lu J., Zhou P., Hu W.,Fang Y., Chen H., Liu X., Shao J., Zhao F., Ding Y., Lin T., Chang H., Zhang J.,Zhang Y., Wang Y. // International Journal of Nanomedicine. – 2014. – Vol.
9. – P.5603 - 5618.127)Mumford J.A. Antigenicity and immunogenicity of equine influenzavaccines containing a Carbomer adjuvant. / Mumford J.A., Wilson H., Hannant D.,Jessett D.M. // Epidemiology and Infection. – 1994. – Vol. 112. – No 2. – P. 421 –437.128)Fachinger V. The effect of vaccination against porcine circovirus type 2 inpigs suffering from porcine respiratory disease complex.
/ Fachinger V., Bischoff R.,Jedidia S.B., Saalmuller A., Elbers K. // Vaccine. – 2008. – Vol. 26. – No 11. – P.1488 – 1499.129)Ohnesorge W.C. One dose vaccination against mycoplasma infections ofpigs. / Ohnesorge W.C., Von Richthofen I.F., Genzow M.,Von Freyburg M., Park K.// United States Patent US8444989 B1, 2013.106130)Mair K.H. Carbopol improves the early cellular immune responses inducedby the modified-life vaccine Ingelvac PRRS MLV. / Mair K.H., Koinig H., GernerW., Höhne A., Bretthauer J., Kroll J.J., Roof M.B., Saalmüller A., Stadler K.,Libanova R. // Veterinary Microbiology.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
